Xiangxue Life Sciences Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Founded in 2015 and based in Guangzhou, China, Xiangxue Life Sciences is a cancer and viral infection drug development company that focuses on the research of T cell receptor technology and TCR-T adoptive immunotherapy. It cooperated with Thermo Fisher, China Academy of Medical Sciences, THE FIRST HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY and other enterprise or facilities. Heping Gong, the vice president and co-founder of the company, has 20 years of experience in drug discovery and development management, and used to work as Chief Scientist of CellTech and UCB Pharma. In March 2021, Xiangxue Life Sciences raised CNY 100 million in strategic investment from new investor Huagai Capital. Xiangxue Life Sciences's main business category is TCR-T overt immunotherapy. Its main business focuses on precision medicine and molecular testing, and its products include TCR-T cell immunotherapy, HLA-A2 antibody. It also provides services such as GMP-grade large-scale lentivirus preparation, cell function identification and animal model validation, T cell and TCR gene cloning, and TCR stability and affinity optimization.

Current Investors

Huagai Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.xlifesc.cn

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.